logo *
 
  * Advocacy   *
 



Advocacy


State of California DRAFT RESOLUTION CALIFORNIA HEPATITIS C TASK FORCE
AN INITIATIVE FOR FEDERAL ASSISTANCE FOR COUNTY HCV COMMUNITY PROGRAMS
DECLARATION OF STATE OF HEALTH EMERGENCY

Resolution in support of Federal funding for California Counties Department of Health Services between county HCV task forces and the local community partnerships for testing, training, education, prevention, medical/Health providers in recognition that this approach will best control the Hepatitis C epidemic in California.
 

WHEREAS California’s public and private healthcare systems have experienced increased demand for Hepatitis C services, including patient and provider education and case management, and are under great economic pressure to treat Hepatitis C, a life threatening liver disease affecting over 1.8 percent of our population and estimated by the CDC, as affecting over 600,000 Californians;
 
WHEREAS Hepatitis C affects Californians from all walks of life, we believe, endorse and encourage the formation and implementation of county task forces to address prevention, education, support, and treatment for all California residents affected by this disease. We affirm the principal that a community response in the form of partnerships between federal, state, and county governments, policy makers, health care providers, educators, the private sector, and community based organizations is an effective way to reduce present and future costs to communities and create new resources to eradicate Hepatitis C;
 
WHEREAS The Hepatitis C Strategic Plan: A Collaborative Approach to the Emerging Epidemic in California (2001), developed by the Steering Committee and Working Group for the Prevention and Control of Hepatitis C in California, recommends the formation of community task forces to address Hepatitis C prevention and control;
 
WHEREAS the leadership of the County Departments of Health in partnership with local agencies has created model HCV Task Forces that encourage cooperative efforts as a community response to this major health concern;
 
WHEREAS the Board of Supervisors of many counties endorse this initiative as a vital means to combat this epidemic through prevention and control and to help restore community's financial health in the face of great costs to treat this disease;
 
WHEREAS it is further noted that the Surgeon General of the United States and the three previous Surgeon Generals have declared this epidemic to be a major national health concern;
 
WHEREAS The State of California, Governor, Lt. Governor and the State Senate and State Assembly unanimously support and encourage action by our federal branches of government to assist and support federal funding to California counties for their programs to effectively reduce the spread of Hepatitis C that affects over 600,000 Californians;
 
RESOLVED That the State of California in recognition of this initiative, further convey to the President of the United States therefore be it
 
RESOLVED That California requires Emergency Federal assistance to address Hepatitis C as a Public Health State of Emergency
 
By my hand and seal: Governor of the State of California
(California State Seal)
 
(Draft by Bill Remak revised 1/29/03)
 

CALIFORNIANS FOR STEM CELL RESEARCH AND CURES
 
Individual Endorsement
 
YES! I support the California Stem Cell Research and Cures Initiative, which will provide funds needed for the development of lifesaving therapies and disease cures that could save the lives of millions of California children and adults. You may list me publicly as a member of the statewide coalition formed to pass this important measure.
 
______________________________________ _______________________________________
*Name of Individual (please print) **Title (if applicable)
 
______________________________________ _______________________________________
**Organization (if applicable)     **Other Titles (e.g., board members, past presidents, etc.)
 
______________________________________ _______________________________________
*Mailing Address City Zip County
 
______________________________________ _______________________________________
*Employer *Occupation
 
______________________________________ ______________________________________
Signature Date Signed
 
______________________________________ _______________________________________
Daytime Phone E-mail address
*Information required by California law for those making contributions
**For identification purposes only
 
Q YES! I am willing to support this effort in other ways. Please contact me about how I may help.  Q Contact by Phone Q Contact by E-Mail
Q I would like to make a contribution to the campaign. Enclosed is a check for  $______________.
Q I am willing to send letters to the editor of local newspapers.
Q Please add me to your volunteer list so I may hand out campaign literature and recruit others to join the coalition.
Q Please add me to your speakers list so I may help by attending events in and around my community.
Q Please add me to your e-mail alert list so I may receive regular updates and pass them on to people in my e-mail address book.
Please mail or fax this completed form to:
Californians for Stem Cell Research and Cures
1438 N. Gower Street, Box 37
Los Angeles, CA 90028
Phone: (323) 468-3391
Fax: (323) 468-3393
Contributions to this committee are not tax deductible for federal or state income tax purposes


ABOUT SIGNING THE MEMBERSHIP FORM
1. By signing the form, you are simply confirming that you can be listed with other citizens who support the proposed initiative measure. This is the only position and the only issue with which your name will be associated.
  2. The citizens on the list will include a broad-based coalition of academic, civic, healthcare, public safety, business, and labor leaders and other citizens from all walks of life.
  3. Lists of citizens, businesses, and organizations supporting the initiative measure may be used in association with materials such as fact sheets, brochures, and possibly in advertisements about the amendment and the measure. All statements in such materials will be based on verifiable facts and information.
  4. All lists will note that titles and affiliations of the citizens included are provided for identification only.
  5. Signing the position form does not obligate you to contribute time or money to any campaign, or attend any meetings, or make any public statements. More active involvement in efforts to support passage of the proposed initiative measure or financial contributions to support such efforts are welcomed, but are entirely voluntary.
  6. Any public relations or political activities undertaken in support of the proposed initiative measure will be conducted in strict compliance with the spirit and letter of all relevant state laws, regulations, and ethical standards.

 
 
CALIFORNIA STEM CELL RESEARCH AND CURES INITIATIVE
 
 
SEC. 1. TITLE
 
This measure shall be known as the “California Stem Cell Research and Cures Act.”
 
 
SEC. 2. FINDINGS AND DECLARATIONS
 
The people of California find and declare the following:
 
Millions of children and adults suffer from devastating diseases or injury that are currently incurable, including Cancer, Diabetes, Heart Disease, Alzheimer’s, Parkinson’s, Spinal Cord injuries, Blindness, Lou Gehrig’s Disease, HIV/AIDS, Mental Health disorders, Multiple Sclerosis, Huntington’s Disease and more than 70 other diseases and injuries.
 
Recently medical science has discovered a new way to attack chronic diseases and injuries. The cure and treatment of these diseases can potentially be accomplished through the use of new regenerative medical therapies including a special type of human cells, called stem cells. These life-saving medical breakthroughs can only happen if adequate funding is made available to advance stem cell research, develop therapies, and conduct clinical trials.
 
About half of California’s families have a child or adult who has suffered or will suffer from a serious, often critical or terminal medical condition that could potentially be treated or cured with stem cell therapies. In these cases of chronic illness or when patients face a medical crisis, the healthcare system may simply not be able to meet the needs of patients or control spiraling costs unless therapy focus switches away from maintenance and toward prevention and cures.
 
Unfortunately, the federal government is not providing adequate funding necessary for the urgent research and facilities needed to develop stem cell therapies to treat and cure diseases and serious injuries. This critical funding gap currently prevents the rapid advancement of research that could benefit millions of Californians.
 
The California Stem Cell Research and Cures Act will close this funding gap by establishing an Institute which will issue bonds to support stem cell research, emphasizing pluripotent stem cell and progenitor cell research and other vital medical technologies, for the development of life-saving regenerative medical treatments and cures.
 
 
SEC. 3. PURPOSE AND INTENT
 
It is the intent of the people of California in enacting this measure to:
 
- Authorize an average of $295 million per year in bonds over a 10-year period to fund stem cell research and dedicated facilities for scientists at California’s universities and other advanced medical research facilities throughout the state.
 
- Maximize the use of research funds by giving priority to stem cell research that has the greatest potential for therapies and cures, specifically focused on pluripotent stem cell and progenitor cell research among other vital research opportunities that cannot, or are unlikely to receive timely or sufficient federal funding, unencumbered by limitations that would impede the research. Research shall be subject to accepted patient disclosure and patient consent standards.
 
- Assure that the research is conducted safely and ethically by including provisions to require compliance with standards based on national models that protect patient safety, patient rights and patient privacy.
 
- Prohibit the use of bond proceeds of this initiative for funding for human reproductive cloning.
 
- Improve the California healthcare system and reduce the long-term healthcare cost burden on California through the development of therapies that treat diseases and injuries with the ultimate goal to cure them.
 
- Require strict fiscal and public accountability through mandatory independent audits, open meetings, public hearings and annual reports to the public. Create an Independent Citizen’s Oversight Committee composed of representatives of the University of California campuses with medical schools; other California universities and California medical research institutions; California disease advocacy groups; and California experts in the development of medical therapies.
 
 
- Protect and benefit the California budget: by postponing general fund payments on the bonds for the first five years; by funding scientific and medical research that will significantly reduce state health care costs in the future; and by providing an opportunity for the state to benefit from royalties, patents, and licensing fees that result from the research.
 
- Benefit the California economy by creating projects, jobs, and therapies that will generate millions of dollars in new tax revenues in our state.
 
- Advance the biotech industry in California to world leadership, as an economic engine for California’s future.
 
 
SEC. 4. Article XXXV is added to the California Constitution to read:
 
             Section 1 There is hereby established the California Institute for Regenerative Medicine ("Institute").
 
             Section 2 The Institute shall have the following purposes:
 
                         (a) To make grants and loans for stem cell research, for research facilities and for other vital research opportunities to realize therapies, protocols, and/or medical procedures that will result in, as speedily as possible, the cure for, and/or substantial mitigation of, major diseases, injuries and orphan diseases.
 
                         (b) To support all stages of the process of developing cures, from laboratory research through successful clinical trials.
 
                         (c) To establish the appropriate regulatory standards and oversight bodies for research and facilities development.
 
Section 3 No funds authorized for, or made available to, the Institute shall be used for research involving human reproductive cloning.
 
             Section 4 Funds authorized for, or made available to, the Institute shall be continuously appropriated without regard to fiscal year, be available and used only for the purposes provided herein, and shall not be subject to appropriation or transfer by the Legislature or the Governor for any other purpose.
 
Section 5 There is hereby established a right to conduct stem cell research which includes research involving adult stem cells, cord blood stem cells, pluripotent stem cells and/or progenitor cells. Pluripotent stem cells are cells that are capable of self-renewal, and have broad potential to differentiate into multiple adult cell types. Pluripotent stem cells may be derived from somatic cell nuclear transfer or from surplus products of in vitro fertilization treatments when such products are donated under appropriate informed consent procedures. Progenitor cells are multipotent or precursor cells that are partially differentiated but retain the ability to divide and give rise to differentiated cells.
 
             Section 6 Notwithstanding any other provision of this Constitution or any law, the Institute, which is established in state government, may utilize state issued tax-exempt and taxable bonds to fund its operations, medical and scientific research, including therapy development through clinical trials, and facilities.
 
             Section 7 Notwithstanding any other provision of this Constitution, including Article VII, or any law, the Institute and its employees are exempt from Civil Service.
 
SEC. 5. Chapter 3 commencing with Section 125281.01 is added to Part 5 of Division 106 of the Health and Safety Code to read:
 
Chapter 3
 
California Stem Cell Research and Cures/Bond Act
 
ARTICLE 1.
 
California Stem Cell Research and Cures Act
 
125281.01 General – Independent Citizen’s Oversight Committee (“ICOC”)
This Chapter implements California Constitution article XXXV which established the California Institute for Regenerative Medicine ("Institute").
125281.02 Creation of the ICOC
There is hereby created the Independent Citizen’s Oversight Committee,
hereinafter, the ICOC, which shall govern the Institute and is hereby vested with full power, authority and jurisdiction over the Institute.
125281.03 ICOC Membership; Appointments; Terms of Office
(a) ICOC Membership
The ICOC shall have 29 members, appointed as follows:
(1) The Chancellors of the University of California at San Francisco, Davis,
San Diego, Los Angeles and Irvine, shall each appoint an executive officer from his or her campus.
(2)   The Governor, the Lieutenant Governor, the Treasurer and the Controller
shall each appoint an executive officer from the following three categories:
(A)  a California university, excluding the five campuses of the University of California described in paragraph (1), that has demonstrated success and leadership in stem cell research, and that has:
(i) a nationally-ranked research hospital and medical school; this criteria
will apply to only two of the four appointments.
(ii) a recent proven history of administering medical research grants and contracts in an average annual range exceeding $100 million.
(iii) a ranking within the past five years in the top 10 United States universities
with the highest number of life-science patents or that has research or clinical faculty who are members of the National Academy of Sciences.
(B) a California non-profit academic and research institution that is not a part of the University of California, that has demonstrated success and leadership in stem cell research, and that has:
(i) a nationally-ranked research hospital or that has research or clinical faculty
who are members of the National Academy of Sciences.
(ii) a proven history in the last five years of managing a research budget in the
lifesciences exceeding $20 million.  
(C) a California life-science commercial entity that is not actively engaged in
  researching or developing therapies with pluripotent or progenitor stem cells, that has a background in implementing successful experimental medical therapies, and that has not been awarded, or applied for, funding by the Institute at the time of appointment. A board member of such entity with a successful history of developing innovative medical therapies may be appointed in lieu of an executive officer.
(D) only one member shall be appointed from a single university, institution, or entity. The executive officer of a California university, a non-profit research institution or life-science commercial entity who is appointed as a member, may from time to time delegate those duties to an executive officer of the entity or to the dean of the medical school, if applicable.
(3) The Governor, the Lieutenant Governor, the Treasurer, and the
Controller shall appoint members from among California representatives of California regional, state, or national disease advocacy groups, as follows:
(A)   The Governor shall appoint two members, one from each of the following disease advocacy groups: spinal cord injury, and Alzheimer’s disease.
(B) The Lieutenant Governor shall appoint two members, one from each of the
following disease advocacy groups: type II diabetes; and multiple sclerosis or
amyotrophic lateral sclerosis.
(C)  The Treasurer shall appoint two members, one from each of the following
  disease groups: type I diabetes and heart disease.
(D) The Controller shall appoint two members, one from each of the
following disease groups: cancer and Parkinson’s disease.
(4) The Speaker of the Assembly shall appoint a member from among
  California representatives of a California regional, state, or national Mental Health
disease advocacy group.
(5) The President Pro Tem of the Senate shall appoint a member from among California representatives of a California regional, state, or national HIV/AIDS disease advocacy group.
(6) A Chairperson and Vice Chairperson who shall be elected by the ICOC members. Within 40 days of the effective date of this Act, each Constitutional Officer shall nominate a candidate for Chairperson and another candidate for Vice Chairperson. The Chairperson and Vice Chairperson shall each be elected for a term of six years. The Chairperson and Vice Chairperson of ICOC shall be full or part-time employees of the Institute and shall meet the following criteria:
(A) Mandatory Chairperson Criteria
(i) Documented history in successful stem cell research advocacy.
(ii) Experience with state and federal legislative processes that must include some experience with medical legislative approvals of standards and/or funding.
(iii) Qualified for appointment pursuant to Section 125281.03 (a) (3),
(4) or (5).
(iv) Cannot be concurrently employed by or on leave from any prospective grant or loan recipient institutions in California.
(B) Additional Criteria for Consideration:
(i) Experience with governmental agencies or institutions (either executive or board position).
(ii)       Experience with the process of establishing government standards and procedures.
(iii) Legal experience with the legal review of proper governmental authority for the exercise of government agency or government institutional powers.
(iv)   Direct knowledge and experience in bond financing.
The Vice-Chairperson shall satisfy section 125281.03 (a) (6) (A) (i), (iii) and (iv). The Vice-Chairperson shall be selected from among individuals who have attributes and experience complementary to those of the Chairperson, preferably covering the criteria not represented by the Chairperson's credentials and experience.
(b) Appointment of ICOC Members
(1) All appointments shall be made within 40 days of the effective date of this Act. In the event that any of the appointments are not completed within the permitted timeframe, the ICOC shall proceed to operate with the appointments that are in place, provided that at least 65 percent of the appointments have been made.
(2) 45 days after the effective date of this Act, the State Controller and the State Treasurer, or if only one is available within 45 days, the other shall convene a meeting of the appointed members of the ICOC to elect a Chairperson and Vice Chairperson from among the individuals nominated by the Constitutional Officers pursuant to section 125281.03 (a) (6).
  (c) ICOC Member Terms Of Office
(1) The members appointed pursuant to section 125281.03 (a) (1), (a) (3), (a) (4), and (a) (5) shall serve eight-year terms, and all other members shall serve six-year terms. Members shall serve a maximum of two terms.
(2)  If a vacancy occurs within a term, the appointing authority shall appoint a replacement member within 30 days to serve the remainder of the term.
(3) When a term expires, the appointing authority shall appoint a member within 30 days. ICOC members shall continue to serve until their replacements are appointed.
125281.04 Majority Vote of Quorum
Actions of the ICOC may be taken only by a majority vote of a quorum of the ICOC.
125281.05 Public and Financial Accountability Standards
(a) Annual Public Report
The Institute shall issue an annual report to the public which sets forth its activities, grants awarded, grants in progress, research accomplishments, and future program directions. Each annual report shall include, but not be limited to, the following: the number and dollar amounts of research and facilities grants; the grantees for the prior year; the Institute’s administrative expenses; an assessment of the availability of funding for stem cell research from sources other than the Institute; a summary of research findings, including promising new research areas; an assessment of the relationship between the Institute’s grants and the overall strategy of its research program; and a report of the Institute’s strategic research and financial plans.
(b) Independent Financial Audit for Review by State Controller
The Institute shall annually commission an independent financial audit of its activities from a certified public accounting firm which shall be provided to the State Controller, who shall review the audit and annually issue a public report of that review.
(c) Citizen’s Financial Accountability Oversight Committee
There shall be a Citizen’s Financial Accountability Oversight Committee chaired by the State Controller. This committee shall review the annual financial audit, the State Controller’s report and evaluation of that audit, and the financial practices of the Institute. The State Controller, the State Treasurer, the President Pro-Tem of the Senate, the Speaker of the Assembly, and the Chairperson of the ICOC shall each appoint a public member of the committee. Committee members shall have medical backgrounds and knowledge of relevant financial matters. The committee shall provide recommendations on the Institute's financial practices and performance. The State Controller shall provide staff support. The committee shall hold a public meeting, with appropriate notice, and with a formal public comment period. The committee shall evaluate public comments and include appropriate summaries in its annual report. The ICOC shall provide funds for the per diem expenses of the committee members and for publication of the annual report.
(d) Public Meeting Laws
(1)  The ICOC shall hold at least two public meetings per year, one of which will be designated as the Institute’s annual meeting. The ICOC may hold additional meetings as it determines are necessary or appropriate.
(2)  The Bagley-Keene Opening Meeting Act, Article 9 (commencing with section 11120) of Chapter 1 of Part 1 of Division 3 of Title 2 of the Government Code, shall apply to all meetings of the ICOC, except as otherwise provided in this section. The ICOC shall award all grants, loans and contracts in public meetings and shall adopt all governance, scientific, medical and regulatory standards in public meetings.
(3) The ICOC may conduct closed sessions as permitted by the Bagley-Keene Open Meeting Act, Government Code section 11126. In addition, the ICOC may conduct closed sessions when it meets to consider or discuss:
(A) Matters involving information relating to patients or medical subjects, the disclosure of which would constitute an unwarranted invasion of personal privacy.
(B) Matters involving confidential intellectual property or work product, whether patentable or not, including, but not limited to, any formula, plan, pattern, process, tool, mechanism, compound, procedure, production data, or compilation of information, which is not patented, which is known only to certain individuals who are using it to fabricate, produce, or compound an article of trade or a service having commercial value and which gives its user an opportunity to obtain a business advantage over competitors who do not know it or use it.
(C) Matters involving pre-publication, confidential scientific research or data.
(D) Matters concerning the appointment, employment, performance, compensation, or dismissal of Institute officers and employees. Action on compensation of the Institute’s officers and employees shall only be taken in open session.
(4)  The meeting required by section 125281.03 (b) (2) shall be deemed to be a special meeting for the purposes of Government Code section 11125.4.
(e) Public Records
(1) The California Public Records Act, Article 1 (commencing with section 6250) of Chapter 3.5 of Division 7 of Title 1 of the Government Code, shall apply to all records of the Institute, except as otherwise provided in this section.
(2) Nothing in this section shall be construed to require disclosure of any records that are any of the following:
(A) Personnel, medical or similar files, the disclosure of which would constitute an unwarranted invasion of personal privacy.
(B) Records containing or reflecting confidential intellectual property or work product, whether patentable or not, including, but not limited to, any formula, plan, pattern, process, tool, mechanism, compound, procedure, production data, or compilation of information, which is not patented, which is known only to certain individuals who are using it to fabricate, produce, or compound an article of trade or a service having commercial value and which gives its user an opportunity to obtain a business advantage over competitors who do not know it or use it.
(C) Pre-publication scientific working papers or research data.
(f) Competitive Bidding
(1) The Institute shall, except as otherwise provided in this section, be governed by the competitive bidding requirements applicable to the University of California, as set forth in Article 1 (commencing with section 10500), Chapter 2.1, Part 2, Division 2 of the Public Contract Code.
(2) For all Institute contracts, the ICOC shall follow the procedures required of the Regents by Article 1 (commencing with section 10500), Chapter 2.1, Part 2, Division 2 of the Public Contract Code with respect to contracts let by the University of California.
(3) The requirements of this section shall not be applicable to grants or loans approved by the ICOC.
(4) Except as provided in this section, the Public Contract Code shall not apply to contracts let by the Institute.
(g) Conflicts of Interest
(1) The Political Reform Act, Title 9 (commencing with section 81000) of the Government Code, shall apply to the Institute and to the ICOC, except as provided in this section and in section 125281.09(e).
(A) No member of the ICOC shall make, participate in making, or in any way attempt to use his or her official position to influence a decision to approve or award a grant, loan or contract to his or her employer, but a member may participate in a decision to approve or award a grant, loan or contract to a non-profit entity in the same field as his or her employer.
(B) A member of the ICOC may participate in a decision to approve or award a grant, loan or contract to an entity for the purpose of research involving a disease from which a member or his or her immediate family suffers or in which the member has an interest as a representative of a disease advocacy organization.
(C) The adoption of standards is not a decision subject to this section.
(2) Service as a member of the ICOC by a member of the faculty or administration of any system of the University of California shall not, by itself, be deemed to be inconsistent, incompatible, in conflict with, or inimical to the duties of the ICOC member as a member of the faculty of administration of any system of the University of California and shall not result in the automatic vacation of either such office. Service as a member of the ICOC by a representative or employee of a disease advocacy organization, a non-profit academic and research institution, or a life science commercial entity shall not be deemed to be inconsistent, incompatible, in conflict with, or inimical to the duties of the ICOC member as a representative or employee of that organization, institution or entity.
(3) Government Code section 1090 shall not apply to any grant, loan or contract made by the ICOC except where both of the following conditions are met:
(A) The grant, loan or contract directly relates to services to be provided by any member of the ICOC or the entity the member represents or financially benefits the member or the entity he or she represents.
(B) The member fails to recuse himself or herself from making, participating in making, or in any way attempting to use his or her official position to influence a decision on the grant loan or contract.
(h) Patent Royalties and License Revenues Paid To The State of California
The ICOC shall establish standards that require that all grants and loan awards be subject to intellectual property agreements that balance the opportunity of the state of California to benefit from the patents, royalties, and licenses that result from basic research, therapy development and clinical trials with the need to assure that essential medical research is not unreasonably hindered by the intellectual property agreements.
(i) Preference for California Suppliers
The ICOC shall establish standards to ensure that grantees purchase goods and services from California suppliers to the extent reasonably possible, in a good faith effort to achieve a goal of more than 50 per cent of such purchases from California suppliers. 
125281.06 Medical and Scientific Accountability Standards
(a) Medical Standards
In order to avoid duplication or conflicts in technical standards for scientific and medical research, with alternative state programs, the Institute will develop its own scientific and medical standards to carry out the specific controls and intent of the Act, notwithstanding Health and Safety Code sections 125300 (b), 125320, 125118, 125118.5, 125119, 125119.3 and 125119.5, or any other current or future state laws or regulations dealing with the study and research of pluripotent stem cells and/or progenitor cells, or other Vital Research Opportunities, except Health and Safety Code section 125315. The ICOC, its working committees and its grantees shall be governed solely by the provisions of this Act in the establishment of standards, the award of grants and the conduct of grants awarded pursuant to this Act.
The ICOC shall establish standards as follows:
(1) Informed Consent
Standards for obtaining the informed consent of research donors, patients, or participants, which initially shall be generally based on the standards in place on January 1, 2003, for all research funded by the National Institutes of Health, with modifications to adapt to the mission and objectives of the Institute.
(2) Controls on Research Involving Humans
Standards for the review of research involving human subjects which initially shall be generally based on the Institutional Review Board standards promulgated by the National Institutes of Health and in effect on January 1, 2003, with modifications to adapt to the mission and objectives of the Institute.
(3) Prohibition on Compensation
Standards prohibiting compensation to research donors or participants, while permitting reimbursement of expenses.
(4) Patient Privacy Laws
Standards to assure compliance with state and federal patient privacy laws.
(5) Limitations on Payments for Cells
Standards limiting payments for the purchase of stem cells or stem cell lines to reasonable payment for the removal, processing, disposal, preservation, quality control, storage, transplantation, or implantation or legal transaction or other administrative costs associated with these medical procedures and specifically including any required payments for medical or scientific technologies, products, or processes for royalties, patent or licensing fees or other costs for intellectual property.
(6) Time Limits for Obtaining Cells
Standards setting a limit on the time during which cells may be extracted from blastocysts, which shall initially be 8 to 12 days after cell division begins, not counting any time during which the blastocysts and/or cells have been stored frozen.
125281.07 ICOC Functions
The ICOC shall perform the following functions:
(a) Oversee the operations of the Institute.
(b) Develop annual and long-term strategic research and financial plans for the Institute.
(c) Make final decisions on research standards and grant awards.
(d) Ensure the completion of an annual financial audit of the Institute’s operations.
(e) Issue public reports on the activities of the Institute.
(f) Establish policies regarding intellectual property rights arising from research funded by the Institute.
(g) Establish rules and guidelines for the operation of the ICOC and its working groups.
(h) Perform all other acts necessary or appropriate in the exercise of its power, authority, and jurisdiction over the Institute.
(i) Select members of the working groups.
(j) Adopt, amend and rescind rules and regulations to carry out the purposes and provisions of this chapter, and to govern the procedures of the ICOC. Except as provided in subdivision (k), these rules and regulations shall be adopted in accordance with the Administrative Procedure Act (Government Code, Title 2, Division 3, Part 1 , Chapter 4.5, Sections 11371 et seq.)
(k) Notwithstanding the Administrative Procedure Act (“APA”), and in order to facilitate the immediate commencement of research covered by this chapter, the ICOC may adopt interim regulations without compliance with the procedures set forth in the APA. The interim regulations shall remain in effect for 270 days unless earlier superseded by regulations adopted pursuant to the APA.
(l) Request the issuance of bonds from the California Stem Cell Research and Cures Finance Committee and loans from the Pooled Money Investment Board.
(m) May annually modify its funding and finance programs to optimize the Institute’s ability to achieve the objective that its activities be revenue-positive for the State of California during its first five years of operation without jeopardizing the progress of its core medical and scientific research program.
(n) Notwithstanding Government Code section 11005, accept additional revenue and real and personal property, including but not limited to gifts, royalties, interest and appropriations that may be used to supplement annual research grant funding and the operations of the Institute.
125281.08 ICOC Operations
(a) Legal Actions and Liability
(1) The Institute may sue and be sued.
(2) Based upon ICOC standards, Institute grantees shall indemnify or insure and hold the Institute harmless against any and all losses, claims, damages, expenses or liabilities, including attorneys’ fees, arising from research conducted by the grantee pursuant to the grant, and/or, in the alternative, grantees shall name the Institute as an additional insured and submit proof of such insurance.
(3) Given the scientific, medical and technical nature of the issues facing the ICOC, and notwithstanding Government Code section 11042, the Institute is authorized to retain outside counsel when the ICOC determines that the Institute requires specialized services not provided by the Attorney General’s Office.
(4) The Institute may enter into any contracts or obligations which are authorized or permitted by law.
(b) Personnel
(1) The ICOC shall from time to time determine the total number of authorized employees for the Institute, up to a maximum of fifty employees, excluding members of the working groups, who shall not be considered Institute employees. The ICOC shall select a Chairperson, Vice-Chairperson and President who shall exercise all of the powers delegated to them by the ICOC. The following functions apply to the Chairperson, Vice-Chairperson and President:
The Chairperson’s primary responsibilities are to manage the ICOC agenda and work flow including all evaluations and approvals of scientific and medical working group grants, loans, facilities, and standards evaluations, and to supervise all annual reports and public accountability requirements; to manage and optimize the Institute’s bond financing plans and funding cash flow plan; to interface with the California legislature, the United States Congress, the California healthcare system, and the California public; to optimize all financial leverage opportunities for the Institute; and to lead negotiations for intellectual property agreements, policies, and contract terms. The Chairperson shall also serve as a member of the Scientific and Medical Accountability Standards Working Group and the Scientific and Medical Research Facilities Working Group and as an ex-officio member of the Scientific and Medical Research Funding Working Group. The Vice-Chairperson’s primary responsibilities are to support the Chairperson in all duties and to carry out those duties in the Chairperson’s absence.
The President’s primary responsibilities are to serve as the Chief Executive of the Institute; to recruit the highest scientific and medical talent in the United States to serve the Institute on its Working Groups; to serve the Institute on its Working Groups; to direct ICOC staff and participate in the process of supporting all Working Group requirements to develop recommendations on grants, loans, facilities, and standards as well as to direct and support the ICOC process of evaluating and acting on those recommendations, the implementation of all decisions on these and general matters of the ICOC; to hire, direct, and manage the staff of the Institute; to develop the budgets and cost control programs of the Institute; to manage compliance with all rules and regulations on the ICOC, including the performance of all grant recipients; and to manage and execute all intellectual property agreements and any other contracts pertaining to the Institute or research it funds.
(2) Each member of the ICOC except the Chairperson, Vice Chairperson and President, shall receive a per diem of one hundred dollars ($100) per day (adjusted annually for cost of living) for each day actually spent in the discharge of the member’s duties, plus reasonable and necessary travel and other expenses incurred in the performance of the member’s duties.
(3) The ICOC shall establish daily consulting rates and expense reimbursement standards for the non-ICOC members of all of its working groups.
(4) Notwithstanding Government Code section 19825, the ICOC shall set compensation for the Chairperson, Vice-Chairperson and President and other officers, and for the scientific, medical, technical, and administrative staff of the Institute within the range of compensation levels for executive officers and scientific, medical, technical, and administrative staff of medical schools within the University of California system and the non-profit academic and research institutions described in section 125281.03 (a) (2).
125281.09 Scientific and Medical Working Groups-General
(a) The Institute shall have, and there is hereby established three separate scientific and medical working groups as follows:
Scientific and Medical Research Funding Working Group;
Scientific and Medical Accountability Standards Working Group; and
Scientific and Medical Research Facilities Working Group
(b) Working Group Members
Appointments of scientific and medical working group members shall be made by a majority vote of a quorum of the ICOC, within 30 days of the election and appointment of the initial ICOC members. The working group members’ terms shall be six years except that, after the first six year terms, the members’ terms will be staggered so that one-third of the members shall be elected for a term that expires two years later, one third of the members shall be elected for a term that expires four years later, and one-third of the members shall be elected for a term that expires six years later. Subsequent terms are for six years. Working group members may serve a maximum of two consecutive terms.
(c) Working Group Meetings
Each scientific and medical working group shall hold at least four meetings per year, one of which shall be designated as its annual meeting.
(d) Working Group Recommendations to the ICOC
Recommendations of each of the working groups may be forwarded to the ICOC only by a vote of a majority of a quorum of the members of each working group. If 35 percent of the members of any working group join together in a minority position, a minority report may be submitted to the ICOC. The ICOC shall consider the recommendations of the working groups in making its decisions on applications for research and facility grants and loan awards and in adopting regulatory standards. Each working group shall recommend to ICOC rules, procedures and practices for that working group.
(e) Conflict of Interest
(1) The ICOC shall adopt conflict of interest rules, based on standards applicable to members of scientific review committees of the National Institutes of Health, to govern the participation of non-ICOC working group members.
(2) The ICOC shall appoint an ethics officer from among the staff of the Institute.
(3) Because the working groups are purely advisory and have no final decision-making authority, members of the working groups shall not be considered public officials, employees or consultants for purposes of the Political Reform Act (commencing with Government Code section 81000), Government Code sections 1090 and 19990, and Public Contract Code sections 10516 and 10517.
(f) Working Group Records
All records of the working groups submitted as part of the working groups’ recommendations to the ICOC for approval shall be subject to the Public Records Act.  Except as provided in this subdivision, the working groups shall not be subject to the provisions of Article 9 (commencing with Section 11120) of Chapter 1 of Part 1 of Division 3 of Title 2 of the Government Code, or Article 1 (commencing with Section 6250) of Chapter 3.5 of Division 7 of Title 1 of the Government Code.
125281.10 Scientific and Medical Accountability Standards Working Group
(a) Membership
The Scientific and Medical Accountability Standards Working Group shall have 19 members as follows:
(1) Five ICOC members from the ten groups that focus on disease-specific areas described in section 125281.03 (a) (3), (a) (4) and (a) (5).
(2) Nine scientists and clinicians nationally recognized in the field of pluripotent and progenitor cell research.
(3) Four medical ethicists.
(4) The chairperson of the ICOC.
(b) Functions
The Scientific and Medical Accountability Standards Working Group shall have the following functions:
(1) To recommend to the ICOC scientific, medical and ethical standards.
(2) To recommend to the ICOC standards for all medical, socio-economic, and financial aspects of clinical trials and therapy delivery to patients, including, among others, standards for safe and ethical procedures for obtaining materials and cells for research and clinical efforts for the appropriate treatment of human subjects in medical research consistent with section 125281.06 (a) (2) herein, and to ensure compliance with patient privacy laws.
(3) To recommend to the ICOC modification of the standards described in sub-paragraphs (1) and (2) as needed.
(4) To make recommendations to the ICOC on the oversight of funded research to ensure compliance with the standards described in subparagraphs (1) and (2).
(5) To advise the ICOC, the Scientific and Medical Research Funding Working Group, and the Scientific and Medical Research Facilities Working Group on an on-going basis on relevant ethical and regulatory issues.
125281.11 Scientific and Medical Research Funding Working Group
(a) Membership
The Scientific and Medical Research Funding Working Group shall have 23 members as follows:
(1) Seven ICOC members from the 10 disease advocacy group members described in sections 125281.03 (a) (3), (a) (4), and (a) (5).
(2) 15 scientists nationally recognized in the field of stem cell research.
(3) The Chairperson of the ICOC.
(b) Functions
The Scientific and Medical Research Funding Working Group shall perform the following functions:
(1) Recommend to the ICOC interim and final criteria, standards and requirements for considering funding applications and for awarding research grants and loans.
(2) Recommend to the ICOC standards for the scientific and medical oversight of awards.
(3) Recommend to the ICOC any modifications of the criteria, standards and requirements described in subparagraphs (1) and (2) above as needed.
(4) Review grant and loan applications based on the criteria, requirements and standards adopted by the ICOC and make recommendations to the ICOC for the award of research, therapy development, and clinical trial grants and loans.
(5) Conduct peer-group progress oversight reviews of grantees to ensure compliance with the terms of the award, and report to the ICOC any recommendations for subsequent action.
(6) Recommend to the ICOC standards for the evaluation of grantees to ensure that they comply with all applicable requirements. Such standards shall mandate periodic reporting by grantees and shall authorize the Scientific and Medical Research Funding Working Group to audit a grantee and forward any recommendations for action to the ICOC.
(7) Recommend its first grant awards within 60 days of the issuance of the interim standards.
(c) Recommendations for Awards
Award recommendations shall be based upon a competitive evaluation as follows.
(1) Only the 15 scientist members of the Scientific and Medical Research Funding Working Group shall score grant and loan award applications for scientific merit. Such scoring shall be based on scientific merit in three separate classifications—research, therapy development and clinical trials, on criteria including the following:
(A) A demonstrated record of achievement in the areas of pluripotent stem cell and progenitor cell biology and medicine, unless the research is determined to be a Vital Research Opportunity.
(B) The quality of the research proposal, the potential for achieving significant research or clinical results, the timetable for realizing such significant results, the importance of the research objectives, and the innovativeness of the proposed research.
(C) In order to ensure that Institute funding does not duplicate or supplant existing funding, a high priority shall be placed on funding pluripotent stem cell and progenitor cell research that cannot, or is unlikely to, receive timely or sufficient federal funding, unencumbered by limitations that would impede the research. In this regard, other research categories funded by the National Institute of Health shall not be funded by the Institute.
(D) Notwithstanding subparagraph (C), other scientific and medical research and technologies and/or any stem cell research proposal not actually funded by the Institute under subparagraph (C) may be funded by the Institute if at least two-thirds of a quorum of the members of the Scientific and Medical Research Funding Working Group recommend to the ICOC that such a research proposal is a Vital Research Opportunity.
   125281.12 Scientific and Medical Facilities Working Group
(a) Membership
The Scientific and Medical Research Facilities Working Group shall have 11 members as follows:
(1) Six members of the Scientific and Medical Research Funding Working Group.
(2) Four real estate specialists. To be eligible to serve on the Scientific and Medical Research Facilities Working Group, a real estate specialist shall be a resident of California, shall be prohibited from receiving compensation from any construction or development entity providing specialized services for medical research facilities, and shall not provide real estate facilities brokerage services for any applicant for, or any funding by the Scientific and Medical Research Facilities Working Group and shall not receive compensation from any recipient of Institute funding grants.
(3) The Chairperson of the ICOC.
(b) Functions
The Scientific and Medical Research Facilities Working Group shall perform the following functions:
(1) Make recommendations to the ICOC on interim and final criteria, requirements and standards for applications for, and the awarding of, grants and loans for buildings, building leases, and capital equipment; those standards and requirements shall include, among others,
(A) facility milestones and timetables for achieving such milestones;
(B) priority for applications that provide for facilities that will be available for research no more than two years after the grant award;
(C) the requirement that all funded facilities and equipment be located solely within California;
(D) the requirement that grantees comply with reimbursable building cost standards, competitive building leasing standards, capital equipment cost standards, and reimbursement standards and terms recommended by the Scientific and Medical Facilities Funding Working Group, and adopted by the ICOC;
(E) the requirement that grantees shall pay all workers employed on construction or modification of the facility funded by facilities grants or loans of the Institute, the general prevailing rate of per-diem wages for work of a similar character in the locality in which work on the facility is performed, and not less than the general prevailing rate of per diem wages for holiday and overtime work fixed as provided in Division 2, Part 7, Chapter 1 of the Labor Code;
(F) the requirement that grantees be not-for-profit entities;
(G) the requirement that awards be made on a competitive basis, with the following minimum requirements:
(i) that the grantee secure matching funds from sources other than the Institute equal to at least 20 percent of the award. Applications of equivalent merit, as determined by the Scientific and Medical Research Funding Working Group, considering research opportunities to be conducted in the proposed research facility, shall receive priority to the extent that they provide higher matching fund amounts. The Scientific and Medical Research Facilities Working Group may recommend waiving the matching fund requirement in extraordinary cases of high merit or urgency;
(ii) that capital equipment costs and capital equipment loans be allocated when equipment costs can be recovered in part by the grantee from other users of the equipment.
(2) Make recommendations to the ICOC on oversight procedures to ensure grantees' compliance with the terms of an award.
125281.13 Appropriation and Allocation of Funding.
(a) Monies in the California Stem Cell Research and Cures Fund shall be allocated as follows:
(1) No less than 97 percent of the proceeds of the bonds authorized pursuant to section 125282.05, after allocation of bond proceeds to purposes described in subsections (a) (iv) and (a) (v) of section 125282.03, shall be used for grants and grant oversight as provided in this chapter.
(A) Not less than 90 percent of the amount used for grants shall be used for research grants, with no more than the following amounts—as stipulated below— to be committed during the first ten years of grant-making by the Institute with each year’s commitments to be advanced over a period of one to seven years, except that any such funds that are not committed may be carried over to one or more following years. The maximum amount of research funding to be allocated annually as follows: Year 1, 5.6%; Year 2, 9.4%; Year 3, 9.4%; Year 4, 11.3%; Year 5, 11.3%; Year 6, 11.3%; Year 7, 11.3%; Year 8, 11.3%; Year 9, 11.3%; and Year 10, 7.5%.
(B) Not more than three percent of the proceeds of bonds authorized by section 125282.05 may be used by the Institute for research and research facilities implementation costs, including the development, administration and oversight of the grant-making process and the operations of the working groups.
(2)  Not more than three percent of the proceeds of the bonds authorized pursuant to section 125282.05 shall be used for the costs of general administration of the Institute.
(3) In any single year any new research funding to any single grantee for any program year is limited to no more than two percent of the total bond authorization under this Chapter. This limitation shall be considered separately for each new proposal without aggregating any prior year approvals that may fund research activities. This requirement shall be determinative, unless 65 percent of a quorum of the ICOC approves a higher limit for that grantee.
(4) Recognizing the priority of immediately building facilities that ensure the independence of the scientific and medical research of the Institute, up to 10 percent of the proceeds of the bonds authorized pursuant to section 125282.05, net of costs described in clauses (a) (ii), (a) (iv) and (a) (v) of section 125282.03 shall be allocated for grants to build scientific and medical research facilities of non-profit entities which are intended to be constructed in the first five years.
(5) The Institute shall limit indirect costs to 25 percent of a research award, excluding amounts included in a facilities award, except that the indirect cost limitation may be increased by that amount by which the grantee provides matching funds in excess of 20 percent of the grant amount.
(b) To enable the Institute to commence operating during the first six months following the adoption of this measure, there is hereby appropriated from the General Fund as a temporary start-up loan to the Institute three million dollars ($3,000,000) for initial administrative and implementation costs. All loans to the Institute pursuant to this appropriation shall be repaid to the General Fund within twelve months of each loan draw from the proceeds of bonds sold pursuant to section 125282.05.
(c) The Institute’s funding schedule is designed to create a positive tax revenue stream for the state of California during the Institute’s first five calendar years of operations, without drawing funds from the state general fund for principal and interest payments for those first five calendar years.
 
ARTICLE 2.
CALIFORNIA STEM CELL RESEARCH AND CURES BOND ACT OF 2004
125282.01. This article shall be known, and may be cited, as the California Stem Cell Research and Cures Bond Act of 2004.
125282.02. As used in this article, the following terms have the following meaning:
(a) “Act” means the California Stem Cell Research and Cures Act” constituting Chapter 3 (commencing with Section 125281.01) of Part 5 of Division 106 of the Health and Safety Code.
(b) “Board” or “Institute” means the California Institute for Regenerative Medicine designated in accordance with subdivision (b) of Section 125282.07.
(c) “Committee” means the California Stem Cell Research and Cures Finance Committee created pursuant to subdivision (a) of Section 125282.07.
(d) “Fund” means the California Stem Cell Research and Cures Fund created pursuant to Section 125282.04.
(e)  “Interim Debt” means any interim loans pursuant to Sections 125281.13 (b), 125282.11 and 25282.12, bond anticipation notes or commercial paper notes issued to make deposits into the Fund and which will be paid from the proceeds of bonds issued pursuant to this article.
125282.03. (a) Notwithstanding Section 13340 of the Government Code or any other provision of law, moneys in the Fund are appropriated without regard to fiscal years to the Institute for the purpose of (i) making grants or loans to fund research and construct facilities for research, all as described in and pursuant to the Act, (ii) paying general administrative costs of the Institute (not to exceed 3% of the net proceeds of each sale of bonds), (iii) paying the annual administration costs of the Interim Debt or bonds after December 31 of the fifth full calendar year after this article takes effect, (iv) paying the costs of issuing Interim Debt, paying the annual administration costs of the Interim Debt until and including December 31 of the fifth full calendar year after this article takes effect, and paying interest on Interim Debt, if such Interim Debt is incurred or issued on or prior to December 31 of the fifth full calendar year after this article takes effect, and (v) paying the costs of issuing bonds, paying the annual administration costs of the bonds until and including December 31 of the fifth full calendar year after this article takes effect, and paying interest on bonds that accrues on or prior to December 31 of the fifth full calendar year after this article takes effect (except that such limitation does not apply to premium and accrued interest as provided in Section 125282.13). In addition, moneys in the Fund or other proceeds of the sale of bonds authorized by this article may be used to pay principal of or redemption premium on any Interim Debt issued prior to the issuance of bonds authorized by this article. Moneys deposited in the Fund from the proceeds of Interim Debt may be used to pay general administrative costs of the Institute without regard to the 3% limit set forth in (ii) above, so long as such 3% limit is satisfied for each issue of bonds.
(b) Repayment of principal and interest on any loans made by the Institute pursuant to this article shall be deposited in the Fund and used to make additional grants and loans for the purposes of this Act or for paying continuing costs of the annual administration of outstanding bonds.
125282.04. The proceeds of Interim Debt and bonds issued and sold pursuant to this article shall be deposited in the State Treasury to the credit of the California Stem Cell Research and Cures Fund, which is hereby created in the State Treasury, except to the extent that proceeds of the issuance of bonds are used directly to repay Interim Debt.
125282.05. Bonds in the total amount of three billion dollars ($3,000,000,000), not including the amount of any refunding bonds issued in accordance with Section 125282.14, or as much thereof as is necessary, may be issued and sold to provide a fund to be used for carrying out the purposes expressed in this article and to be used and sold for carrying out the purposes of Section 125282.03 and to reimburse the General Obligation Bond Expense Revolving Fund pursuant to Section 16724.5 of the Government Code. The bonds, when sold, shall be and shall constitute a valid and binding obligation of the State of California, and the full faith and credit of the State of California is hereby pledged for the punctual payment of both the principal of, and interest on, the bonds as the principal and interest become due and payable.
125282.06. The bonds authorized by this article shall be prepared, executed, issued, sold, paid, and redeemed as provided in the State General Obligation Bond Law (Chapter 4 (commencing with Section 16720) of Part 3 of Division 4 of Title 2 of the Government Code), and all of the provisions of that law except Section 16727 apply to the bonds and to this article and are hereby incorporated in this article as though set forth in full in this article.
125282.07. (a) Solely for the purpose of authorizing the issuance and sale, pursuant to the State General Obligation Bond Law, of the bonds and Interim Debt authorized by this article, the California Stem Cell Research and Cures Finance Committee is hereby created. For purposes of this article, the California Stem Cell Research and Cures Finance Committee is “the Committee” as that term is used in the State General Obligation Bond Law. The committee consists of the Treasurer, the Controller, the Director of Finance, the Chairperson of the California Institute for Regenerative Medicine, and two other members of the Independent Citizens Oversight Committee (as created by the Act) chosen by the Chairperson of the California Institute for Regenerative Medicine, or their designated representatives. The Treasurer shall serve as chairperson of the Committee. A majority of the Committee may act for the Committee.
(b)  For purposes of the State General Obligation Bond Law, the California Institute for Regenerative Medicine is designated the “board.”
125282.08. (a) The Committee shall determine whether or not it is necessary or desirable to issue bonds authorized pursuant to this article in order to carry out the actions specified in this article and, if so, the amount of bonds to be issued and sold. Successive issues of bonds may be authorized and sold to carry out those actions progressively, and it is not necessary that all of the bonds authorized to be issued be sold at any one time. The bonds may bear interest which is includable in gross income for federal income tax purposes if the Committee determines that such treatment is necessary in order to provide funds for the purposes of the Act.
(b) The total amount of the bonds authorized by Section 125282.05 which may be issued in any calendar year, commencing in 2005, shall not exceed $350,000,000. If less than this amount of bonds is issued in any year, the remaining permitted amount may be carried over to one or more subsequent years.
(c) An interest-only floating rate bond structure will be implemented for Interim Debt and bonds until at least December 31 of the fifth full calendar year after this article takes effect, with all interest to be paid from proceeds from the sale of Interim Debt or bonds, to minimize debt service payable from the general fund during the initial period of basic research and therapy development, if the Committee determines, with the advice of the Treasurer, that this structure will result in the lowest achievable borrowing costs for the State during that five-year period considering the objective of avoiding any bond debt service payments, by the State's general fund, during that period. Upon such initial determination, the Committee may delegate, by resolution, to the Treasurer such authority in connection with issuance of bonds as it may determine, including but not limited to the authority to implement and continue this bond financing structure (including during any time following the initial five-year period) and to determine that an alternate financing plan would result in significant lower borrowing costs for the State consistent with the objectives related to the State's general fund and to implement such alternate financing plan.
125282.09. There shall be collected each year and in the same manner and at the same time as other State revenue is collected, in addition to the ordinary revenues of the State, a sum in an amount required to pay the principal of, and interest on, the bonds maturing each year. It is the duty of all officers charged by law with any duty in regard to the collection of the revenue to do and perform each and every act that is necessary to collect that additional sum.
125282.10. Notwithstanding Section 13340 of the Government Code, there is hereby appropriated from the General Fund in the State Treasury, for the purposes of this article, an amount that will equal the total of the following:
(a) The sum annually necessary to pay the principal of, and interest on, bonds issued and sold pursuant to this article, as the principal and interest become due and payable.
(b) The sum necessary to carry out Section 125282.11 appropriated without regard to fiscal years.
125282.11. The Director of Finance may authorize the withdrawal from the General Fund of an amount or amounts not to exceed the amount of the unsold bonds that have been authorized by the Committee to be sold for the purpose of carrying out this article. Any amount withdrawn shall be deposited in the Fund. Any money made available under this section shall be returned to the General Fund, plus an amount equal to the interest that the money would have earned in the Pooled Money Investment Account, from money received from the sale of bonds for the purpose of carrying out this article.
125282.12. The Institute may request the Pooled Money Investment Board to make a loan from the Pooled Money Investment Account in accordance with Section 16312 of the Government Code for the purposes of carrying out this article. The amount of the request shall not exceed the amount of the unsold bonds that the Committee, by resolution, has authorized to be sold for the purpose of carrying out this article. The Institute shall execute any documents required by the Pooled Money Investment Board to obtain and repay the loan. Any amounts loaned shall be deposited in the Fund to be allocated by the Institute in accordance with this article.
125282.13. All money deposited in the Fund that is derived from premium and accrued interest on bonds sold shall be reserved in the Fund and shall be available for transfer to the General Fund as a credit to expenditures for bond interest.
125282.14. The bonds may be refunded in accordance with Article 6 (commencing with Section 16780) of Chapter 4 of Part 3 of Division 4 of Title 2 of the Government Code, which is a part of the State General Obligation Bond Law. Approval by the voters of the State for the issuance of the bonds described in this article includes the approval of the issuance of any bonds issued to refund any bonds originally issued under this article or any previously issued refunding bonds.
125282.15. Notwithstanding any provision of this article or the State General Obligation Bond Law, if the Treasurer sells bonds pursuant to this article that include a bond counsel opinion to the effect that the interest on the bonds is excluded from gross income for federal tax purposes, subject to designated conditions, the Treasurer may maintain separate accounts for the investment of bond proceeds and the investment earnings on those proceeds. The Treasurer may use or direct the use of those proceeds or earnings to pay any rebate, penalty, or other payment required under federal law or to take any other action with respect to the investment and use of bond proceeds required or desirable under federal law to maintain the tax-exempt status of those bonds and to obtain any other advantage under federal law on behalf of the funds of this state.
125282.16. Inasmuch as the proceeds from the sale of bonds authorized by this article are not “proceeds of taxes” as that term is used in Article XIII B of the California Constitution, the disbursement of these proceeds is not subject to the limitations imposed by that article.
 
ARTICLE 3.
 
DEFINITIONS
 
125283.01 As used in this Chapter and in Article XXXV of the California Constitution, the following terms have the following meanings:
  (a) “Act” means the California Stem Cell Research and Cures Act constituting Chapter 3 (commencing with Section 125281.01) of Part 5 of Division 106 of the Health and Safety Code.
  (b) “Adult Stem Cell” means an undifferentiated cell found in a differentiated tissue in an adult organism that can renew itself and may (with certain limitations) differentiate to yield all the specialized cell types of the tissue from which it originated.
  (c)  “Capitalized Interest” means interest funded by bond proceeds.
  (d) “Committee” means the California Stem Cell Research and Cures Finance Committee created pursuant to subdivision (a) of Section 125282.07.
  (e) “Constitutional Officers” shall mean the Governor, Lieutenant Governor, Treasurer and Controller of California.
  (f) “Facilities” means buildings, building leases, or capital equipment.
  (g) “Floating-rate bond” means bonds which do not bear a fixed rate of interest until their final maturity date, including commercial paper notes.
  (h) “Fund” means the California Stem Cell Research and Disease Cures Fund created pursuant to Section 125282.04.
  (i) “Grant” means a grant, loan or guarantee.
  (j) “Grantee” means a recipient of a grant from the Institute. All University of California grantee institutions shall be considered as separate and individual grantee institutions.
  (k) “Human Reproductive Cloning” means the practice of creating or attempting to create a human being by transferring the nucleus from a human cell into an egg cell from which the nucleus has been removed for the purpose of implanting the resulting product in a uterus to initiate a pregnancy.
  (l) “Indirect Costs” mean the recipient’s costs in the administration, accounting, general overhead and general support costs for implementing a grant or loan of the Institute. NIH definitions of indirect costs will be utilized as one of the bases by the Scientific and Medical Research Standards Working Group to create a guideline for recipients on this definition, with modifications to reflect guidance by the ICOC and this Act.
  (m) “Institute” means the California Institute for Regenerative Medicine.
  (n) “Interim Standards” means temporary standards that perform the same
function as “emergency regulations” under the Administrative Procedure Act (Government Code, Title 2, Division 3, Part 1, Chapter 4.5, sections 11371 et seq) except that in order to provide greater opportunity for public comment on the permanent regulations, remain in force for 270 days rather than 180 days. 
  (o) “Life-Science Commercial Entity” means a firm or organization, headquartered in California, whose business model includes biomedical or biotechnology product development and commercialization.
  (p) “Medical Ethicist” means an individual with advanced training in ethics—who holds a PhD, MA or equivalent training and who spends or has spent substantial time (a) researching and writing on ethical issues related to medicine, and (b) administering ethical safeguards during the clinical trial process, particularly through service on institutional review boards.
  (q) “Pluripotent Cells” means cells that are capable of self-renewal, and have broad potential to differentiate into multiple adult cell types. Pluripotent stem cells may be derived from somatic cell nuclear transfer or from surplus products of in vitro fertilization treatments when such products are donated under appropriate informed consent procedures. These excess cells from in vitro fertilization treatments would otherwise be intended to be discarded if not utilized for medical research.
  (r) “Progenitor Cells” means multipotent or precursor cells that are partially differentiated but retain the ability to divide and give rise to differentiated cells.
  (s) “Quorum” means at least 65 percent of the authorized membership who are eligible to vote.
  (t) “Research Donor” means a human who donates biological materials for research purposes after full disclosure and consent.
  (u) “Research Funding” includes interdisciplinary scientific and medical funding for basic research, therapy development, and the development of pharmacologies and treatments through clinical trials. When a facilities grant or loan has not been provided to house all elements of the research, therapy development, and/or clinical trials, research funding shall include an allowance for a market lease rate of reimbursement for the facility.  In all cases, operating costs of the facility, including but not limited to library and communication services, utilities, maintenance, janitorial and security, shall be included as direct research funding costs. Legal costs of the Institute incurred in order to negotiate standards with federal and state governments and research institutions; to implement standards or regulations; to resolve disputes; and/or to carry out all other actions necessary to defend and/or advance the Institute’s mission shall be considered direct research funding costs.
  (v) “Research Participant” means a human enrolled with full disclosure and consent, and participating in clinical trials.
  (w) “Revenue Positive” means all state tax revenues generated directly and indirectly by the research and facilities of the Institute are greater than the debt service on the state bonds actually paid by the state general fund in the same year.
  (x) "Stem Cells” mean non-specialized cells that have the capacity to divide in culture and to differentiate into more mature cells with specialized functions.
  (y) “Vital Research Opportunity” means scientific and medical research and technologies and/or any stem cell research not actually funded by the Institute under Section 125281.11 (c) (1) (C) which provides a substantially superior research opportunity vital to advance medical science as determined by at least a two-thirds vote of a quorum of the members of the Scientific and Medical Research Funding Working Group and recommended as such by that working group to the ICOC. Human reproductive cloning shall not be a vital research opportunity.
  SEC. 6. Government Code section 20069 is amended to read as follows:
(a) "State service" means service rendered as an employee or officer (employed, appointed or elected) of the state, the California Institute for Regenerative Medicine and the officers and employees of its governing body, the university, a school employer, or a contracting agency, for compensation, and only while he or she is receiving compensation from that employer therefore, except as provided in Article 4 (commencing with Section 20990) of Chapter 11.
(b) State service," solely for purposes of qualification for benefits and retirement allowances under this system, shall also include service rendered as an officer or employee of a county if the salary for the service constitutes compensation earnable by a member of this system under section 20638.
SEC. 7.            Severability
If any provision of this Act, or part thereof, is for any reason held to be invalid or unconstitutional, the remaining provisions shall not be affected, but shall remain in full force and effect, and to this end the provisions of this Act are severable.
SEC. 8. Amendments
The statutory provisions of this measure, except the bond provisions, may be amended to enhance the ability of the Institute to further the purposes of the grant and loan programs created by the measure, by a bill introduced and passed no earlier than the third full calendar year following adoption, by seventy percent of the membership of both houses of the Legislature and signed by the Governor, provided that at least 14 days prior to passage in each house, copies of the bill in final form shall be made available by the clerk of each house to the public and news media.
 

LEGISLATIVE ALERT
 
In light of the Governor's recent proposal to eliminate development of stem cell research guidelines as part of his budget, we are asking all advocates of stem cell research and their affiliates to contact the Governor's office as soon as possible, with as many letters or communications as possible, asking him to reverse his decision to repeal these guidelines.
Attached is a fact sheet on the Governor's proposal that may help in constructing messages to the Governor.
  The basic themes Sen. Ortiz is stressing in her letter to the Governor are:
Stem cell research guidelines are necessary to maintain and promote California's position as a world leader in stem cell research;
* Scientific guidelines will help attract the best and brightest stem cell scientists to California by further distinguishing California's program from that of other states;
* The oversight provided by SB 322 (Ortiz) will help build public confidence in the research and build support for public financing of the research, which are vital to advancing the research and the cures and treatments that are dependent on the research (feel free to list examples);
* Repeal of the guidelines sends a confusing message to researchers, patients, their families, and the public about California's commitment to stem cell research;
* The minor investment required to develop the guidelines is dwarfed by the enormous medical, scientific, and economic benefits that they will bring to the state.
  Letters and communications may be sent by letter, fax, and/or email to the following address:
Governor Arnold Schwarzenegger
State Capitol Building
Sacramento, CA 95814
Phone: 916-445-2841
Fax: 916-445-4633
governor@governor.ca.gov
 
To assist us in following up with the Governor's Office, it would be helpful if you could fax or email copies or your correspondence to Senator Ortiz's office,
State Capitol, Room 5114, Sacramento, CA, 95814;
916-323-2263 (fax).
Email copies can be sent to me at Peter.Hansel@sen.ca.gov
  Thank you for your help with this. With your help we have a chance to overturn this proposal.
  Peter Hansel
Senate Health and Human Services Committee
 
Fact Sheet on Governor’s Proposal to Repeal
Stem Cell Research Guidelines
Summary of Governor’s Proposal:
  The proposal is included in a memo dated January 9, 2004 from the Department of Finance to the legislative budget chairs, outlining proposals for trailer bill language to implement the Governor’s budget that was released last week.
  The specific proposal would be to repeal the portions of SB 322 (Ortiz) that require the Department of Health Services to develop guidelines to address legal and ethical issues involved in embryonic stem cell research, to convene a technical advisory committee, to collect information from local institutional review boards (IRB)s on the number of embryonic stem cell research projects reviewed and approved, and to report to the Legislature.
  Significance of Issue:
  SB 322 is significant for a number of reasons:
It helps implement the broader policy contained in SB 253 (Ortiz), which authorizes stem cell research in all forms in California but states that consideration of ethical and legal issues be given;
  It further promotes California’s world leadership in stem cell research;
It ensures a check on inappropriate research, for example that venturing into human cloning, and helps build public confidence in the research and public receptivity to public financing for the research;
  It is consistent with the recommendations of the California Advisory Committee on Human Cloning, which recommended in January, 2002 that California permanently ban human reproductive cloning but allow therapeutic cloning subject to reasonable oversight;
  Due to the restrictions on NIH funding for embryonic stem cell research, there are no federal guidelines for federally funded research; there are currently no checks on privately funded research.
  Fiscal Impact:
The Department of Finance estimates that implementation of SB 322 (Ortiz) would entail $233,000 in initial costs to implement the bill, and ongoing annual costs of $28,000 for monitoring and reporting functions. These costs include staff time and contractor costs to convene the stem cell research advisory committee; develop, print, and disseminate the guidelines; collect information from local IRBs; and report to the Legislature.
  Examples of issues to be addressed in guidelines:
  Conditions under which unused embryos and eggs may be donated for research
  Assurances that embryos, eggs, and somatic material have been donated with informed consent;
  Protections against conflicts of interest on the part of researchers and/or fertility conflicts, e.g. through joint ownership or operating agreements;
  Timetables for derivation of stem cells from developing embryos;
  A means of ensuring that projects do not venture into the area of human cloning.
 

Governor Arnold Schwarzenegger
State Capitol Building
Sacramento, CA 95814
Re: SB 322
January 15,2004
  Dear Governor Schwarzenegger,
  Hepatitis C is a very significant unmet medical need with several large pharmaceutical companies actively researching new treatments. Worldwide, approximately 170 million people are currently infected with HCV, and it is estimated that this number will increase to 500 million by 2010. There are a number of different forms, or genotypes, of HCV with genotype one being the most predominant in the United States as well as the most difficult to cure. The only treatment currently available is a combination of ribavirin with interferon or pegylated interferon. This treatment requires up to 48 weeks and causes severe side effects for many patients. The success rate is very limited, especially against genotype one, with a success rate that varies according to the patient's general health and how advanced their liver disease is.
  The CDC estimates that this particular liver disease may have infected over 650,000 Californians and most of them are unaware that they carry this illness. Nearly 35% of persons who die from AIDS's succumb due to this disease. It is estimated that larger proportions of hepatitis patients also suffer from Arthritis, Diabetes, Heart Disease, Cancer and others that cause great suffering.
  We are desperate to develop new and better treatments and vaccines with the hopes to cure many serious major health concerns that plague our fellow citizens, our health care system and overwhelm our medical providers. We have an opportunity for California to emerge and excel as the leaders of Science and Medicine in the recovery of our health and economy as well.
  When we heard that you were considering repealing this historic landmark law, SB 322 in an effort to reduce the budget, we were amazed that your promise to serve the people of our great state might be overshadowed by concepts of expediency on the short term. Sacrificing our long-term benefits to Californians and the leadership to the chronically ill throughout the world is not the answer. We implore you to not repeal this important law and to further support medical research and a greater health consciousness in California.
  Sincerely,
  Bill Remak, Chairman
California Hepatitis C Task Force


Governor Arnold Schwarzenegger
State Capitol Building
Sacramento, CA 95814
 
January 15, 2004             Re: SB 322
 
Dear Governor Schwarzenegger,
 
I am writing to express my grave concern regarding your proposed repeal of SB 322. Do you know that more than 56 million Americans suffer from heart disease? That more than 10 million suffer from some type of cancer? More than 4 million Americans have Alzheimer’s disease, and that number, as we all know, only stands to grow exponentially as our baby boomers age. More than 16 million Americans suffer from diabetes, 40 million from arthritis, 17 million from depression, more than 3 million Americans suffer from stroke and more than 28 million suffer from osteoporosis. Each one of these can cause terrible suffering and pain, in addition to the fiscal burden the illness places on the family, and ultimately, on society. The cost of care for spinal cord injured Californians is likely to exceed $1.2 billion.[1]
 
Each one of these diseases can potentially be cured or substantially mitigated by treatments developed through pluripotent and progenitor cell research. Scientific leaders throughout the world agree that this research must be supported. Even experts in the field of adult stem cell research are quick to support simultaneous investigation into pluripotent and progenitor cell research, knowing that adult stem cell therapies have limitations.
 
We are desperate to develop new and better treatments and vaccines with the hopes to cure many serious major health concerns that plague our fellow citizens, our health care system and overwhelm our medical providers.
 
We have an opportunity for California to emerge and excel as the leader of Science and Medicine in the recovery of our health and our economy. We cannot afford to continue to throw money at maintaining chronic illness ~ our budget woes will only increase. The polio vaccine, developed with NIH funds, saves this country, by some estimates, $30 billion annually.[2] Tuberculosis treatments developed with NIH funds save the country $5 billion annually in institutional care costs.[3] For a variety of reasons, the NIH is unable to move forward in this most promising area of research and we must step up to the plate. Fiscally, morally, and ethically we must find cures. Research supported by SB 322 is regarded throughout the world as the most promising method of finding those cures.
 
When I heard that you were considering repealing this historic landmark law, SB 322 in an effort to reduce the budget, I was amazed that your promise to serve the people of our great state might be overshadowed by concepts of expediency on the short term. Sacrificing our long-term benefits to Californians and the leadership to the chronically ill throughout the world is not the answer. I implore you allow SB 322 to proceed as it was passed and to further support medical research and a greater health consciousness in California.
 
Very Sincerely Yours,
 
 
 
Amy Daly, RN
3859 Bret Harte Drive
Redwood City, CA 94061-1115
650-367-0297


[1] Statistics provided by the American Heart Association, American Cancer Society, Alzheimer’s Association, American Diabetes Association, Arthritis Foundation, Alliance for Aging Research, National Depressive and Manic Depressive Association, National Stroke Association, and Rutgers University study, “Spinal Cord Injury: An Analysis of Medical and Social Costs” (1998, Demos Medical Publishing, Inc.)
[2] Kirschner, Marc and others. 1994. "The Role of BioMedical Research in Health Care Reform." Science, v. 266, no 5182, October 7, pp 49-51
[3] Wisconsin Association of Biomedical Research and Education (1995). Bioscience Research, Development and Industry: Impact on Health and Economic Growth in Wisconsin. Available on line at http://www.wabre.org

HEPATITIS C SHOULDN’T BE IGNORED DUE TO FEAR OF BIOTERRORISM

By Bill Remak - 1/25/2003                              
Chairman, California Hepatitis C Task Force
wmremak@californiahcvtaskforce.org
(707) 773-4922

We all have heard post 9/11 bioterrorism threats centered on using anthrax and smallpox as weapons. But the United States is presently under attack by a “silent epidemic” that is much more insidious because it is doing its killing right under our noses while efforts to combat it are at best, less than adequate.
Hepatitis C (HCV) currently is killing at an annual rate five times higher than the number that perished at the hands of terrorists at the World Trade Center. To suggest that the liver-effecting virus could be used as a terrorist threat may be a bit absurd. But after considering facts how this “silent killer” is taxing our health care system, which is to define the meaning of absurdity?
Over the past five years our society has heard more and more about HCV. The media has dubbed it the "silent killer" and the "silent epidemic" because it takes 20 to 30 years under normal conditions until liver damage becomes so serious it impacts a person’s life.
Most people are unaware they are infected until symptoms arise or their family doctor chances upon some abnormal results from blood tests. Although complications from HCV can cause cirrhosis, liver failure, liver cancer and death, doctors estimate that 15 to 25 percent of those infected fight off the disease with a healthy immune system.
The remaining percentage of people can respond to treatments currently being used, and can be cleared of the virus 40 to 80 percent of the time depending on what strain or genotype they have.
The most prevalent strain in the United States provides encouraging results only in about 40 percent of the patients. When the disease has advanced too far, the only options are surgical procedures and possibly a liver transplant. But over 2000 men, women and children listed on the United Network for Organ Sharing (UNOS) died while waiting for a liver transplant in 2002. This year, thousands nervously await word of suitable livers fearing death as time runs out.
The HCV virus is transmitted through blood contact. Before 1992 there was no test to detect the virus at blood banks. Those who received blood and those who did not practice accepted sanitary precautions prior to that time were at risk. How much at risk? More than five times greater than contracting HIV or AIDS! Something to think about in this day and age where tattooing and piercing is very commonly done by non-professionals who do not take proper health precautions.
The Center for Disease Control estimates that 1.8 percent of our general population is infected with HCV. When you include the homeless and prison inmates that number could swell as high as 2.2 percent.
But could this virus be transported and a delivery system be devised so terrorists could damage or threaten our security, our way of life or our financial stability? Not very likely, but it has not been studied. If used in this manner, it would have to be done manually by an individual using infected blood to contaminate others, spraying it on surgical equipment, injecting it into blood bags for surgical use or directly into patients. That is feasible but not practical. The disease used as a biological agent of “mass destruction” would be ineffective in terms of immediate reaction.
A person exposed in a controlled setting such as a nurse accidentally stuck by a contaminated syringe may take six to eight weeks before providing an accurate test result.
We must consider that the conditions regarding our security systems in hospitals, laboratories and blood banks need to be studied as an issue of national security. We should look carefully at the potential possibilities of malicious transmission of this virus.
The psychological ramifications of not knowing if one has been infected could cause serious panic if citizens are not otherwise considered at high risk and cannot find an explanation for their exposure. This issue undoubtedly needs further study.
The cost of treating HCV today is staggering. Considering current rates of chronic infection, state health care systems are powerless to absorb this great financial strain. In any case, many believe that current treatments to rid individuals of the disease will be improved and perhaps a vaccine will be developed in 20 to 30 years. Why not sooner?
Hepatitis C is among the ten most costly diseases to treat. Increased action and education must be utilized to keep this statistic from getting any worse. How can we best be prepared? We are better off being in the know or at least our government must invest some serious time and money to research this to find out.
It is time to change our course! We should be saving lives; not taking them…this is our right! ] 12/20/2002
 
(Edited by Rob Akers 1/25/03)
 
Comments:
 
" That was an interesting and thought provoking article you wrote about
the potential of bio-terrorism and blood borne pathogens like Hepatitis C.
Definitely something for our Government to think about!"
Steve Kersker
 
" I wrote it to give some balance to this incredible focus on bio-terrorism
and an attempt to remind them that there is a bigger battle already going
on and not to dismantle our health system under the guise of war. That
would give terrorists an easy victory. Unless I created the thought of an
association, they just would not see it."
Bill Remak
 
" This topic requires this kind of language to get the point across."
Phyllis Borchardt
 
" Interesting article and I sent it out on the listserv."
Phyllis Beck
 
" I think it's a good idea to put this out. We need a mechanism to get
more attention. All the attention is given to small pox when really more
attention needs to be given to a "real" threat that is already at our doors.
As much as I hate to say it, we need to get people concerned...."
Kathie Lustig
 
 
" The article is provocative."
Liz Poulsen
 
Nice job on your article re: Hepatitis C and bio-terrorism. Well written!
Dr. John Zweifler
 
 
 
" Steve Kersker phoned me from Florida and I said I just wanted to get people thinking about
it and encouraged it to get distributed to as many as possible especially the media. I told him
that it really isn't important who puts their name on it, as it is the issue that is important. The
whole thing with this Homeland Security and Bio-terrorism hype is that our executive branch is
oblivious to our plight as citizens who are faced with homelessness and dying of treatable
diseases and reducing our education systems to rubble. Many more are suffering here than
will die in this "war" on distant soils. The money being tossed away would otherwise cure cancer,
hepatitis, AIDS and other diseases, send a dozen people to the moon and back, bring our economy back to stability, deal with our country's massive substance abuse problem head on and reduce our staggering unemployment. It is time we shout and take a stand and fight back using the democratic system to do it. We are not being protected but rather we are being abandoned.
 
Tonight I watched 60 minutes in horror to learn that firms were pirating medications for transplant
patients, cancer, hepatitis and aids patients as these are the most costly prescribed drugs, and
were diluting them and putting them back into the market place right under the noses of the major
pharmaceutical manufacturers who knew about it and didn't even report it to the FDA for fear
those consumers would go to their competitors!
 
Tampering With Prescription Drugs?
http://www.cbsnews.com/stories/2002/12/20/60minutes/main533860.shtml
CBS News Online."
Bill Remak
 
It's concise and makes it clearer that no one in its right mind would use HCV as a weapon. I think there may be some room for further editing, but it may start losing some of the message. A good effort. The only thing that leaves me thinking is if the terrorism angle is the only one that can be used to perk up the reader's interest. Ultimately the premise of HCV as a weapon is there just for shock value, not as a serious concept. Even the comparison between the WTC tragedy and the HCV deaths stands on uneasy ground in the mind of the public, the latter lacking the visual and emotional impact of a jetliner striking a tower and sending thousands of souls to their death. HCV is just as tragic, but is played quietly and intimately within the lives of the sufferers and their families.
Corrado Conti
 
 
 
                                            
I see California legislation as a reflection of the goals of the CDC National Hepatitis C Prevention Strategy:
 
(A)  To lower the incidence of acute hepatitis C in the United States
 
(B) Reduce the disease burden from chronic HCV infection.
 
Legislation required in California includes:
 
(1) harm reduction programs directed at persons at increased risk for infection to reduce the
incidence of new HCV infections;
 
 (2) counseling, testing, and medical evaluation and management of
       infected persons to control HCV-related chronic liver disease;
 
(3) surveillance to evaluate the effectiveness of prevention activities;
 
(4) education of health care and public health professionals to improve the
       identification of persons at risk for HCV infection and ensure appropriate
       counseling, diagnosis, medical management, and treatment;
 
(5) education of the public and persons at risk for infection about risk factors
for HCV transmission, and the need for testing and medical evaluation;
 
(6) clinical and public health activities to identify, counsel, and test persons at
risk for HCV infection, and medical evaluation or referral for those found
to be infected;
 
(7) outreach and community-based programs to prevent practices that put
people at risk for HCV infection, and to identify persons who need to get
tested;
 
(8) surveillance to monitor acute and chronic disease trends and evaluate the
effectiveness of prevention and medical care activities; and
 
(9) research to better guide prevention efforts. Hepatitis C prevention activities
must be accessible to persons receiving health care services in both the public
and private sectors.The most effective means to prevent HCV infection and its
consequences is to integrate hepatitis C prevention activities into existing clinical
services and public health programs.
 
In summary, legislation is needed to assist public education, testing, treatment
(when appropriate) and prevention efforts. Current law and the California
Hepatitis C Strategic Plan 2001 provides some sound recommendations, but
lacks a funding solution.
A high-risk population is our correctional institution population. Education,
testing and treatment when appropriate are a high priority in this population.
This should be applied prior to release to the general population.
 
Phyllis D. Borchardt, Director
Public Policy and Advocacy
California Hepatitis C Task Force
41597 Avenida de la Reina
Temecula, CA 92592
(909) 506-1853
E-mail: phyllisb@californiahcvtaskforce.org
©2003California HCV Task Force Bill Remak

 



DONATIONS

Please help and give
what you can.
Thank you
Click here


California Hepatitis C Task Force